The Biotechnology Innovation Organization (BIO) filed a federal complaint on Friday to stop an executive pilot program linking Medicare Part B drug prices to costs in peer nations [1]. BIO and two California-based biotech trade groups submitted the complaint in the U.S. District Court for the Northern District of California to halt the Global Benchmark for Efficient Drug Pricing demonstration, known as GLOBE [4]. The lawsuit asserts that health officials exceeded statutory limits set by Congress [1]. The Centers for Medicare & Medicaid Services (CMS) did not comment on the litigation [4].
BIO Files in Northern California
Trade leaders filed their complaint on Friday, November 7, 2026, asking federal judges to halt the entire drug pricing demonstration before it takes effect [1]. The legal action targets an effort by President Trump to lower spending by aligning American drug payments with levels paid in other wealthy countries [3]. BIO joined two California biotech groups to contest the statutory authority of executive health officials [4]. The groups argue that the pilot alters pricing formulas without explicit authorization from lawmakers [5].
Digital oversight on federal health portals previously drew scrutiny when Australia probed automated system breaches on its Medicare statistics portal. In the California case, BIO and its regional partners filed in the Northern District because California hosts numerous early-stage biotech companies that spend venture capital on clinical trials [4]. A commentary from Mukta AI Editorial in Vesper noted that the industry views international benchmarking as an existential threat to pharmaceutical research and development (R&D) funding. If the court agrees with BIO, a preliminary injunction could freeze the pilot nationwide. The trade group chose litigation over routine lobbying. Federal judges now hold authority over the program’s schedule [5].
Medicare Part B International Benchmark Rules
CMS finalized the GLOBE model on September 30, 2026, to govern physician-administered therapies. Under the design, Medicare compares domestic medicine costs against prices established in 19 economically comparable countries, including Canada, Germany, France, and the United Kingdom. If an American price sits above that international benchmark, the manufacturer owes Medicare a larger rebate [6].
Medicare Part B covers therapies delivered in medical settings and not pills picked up at retail pharmacies. Covered medications include cancer drugs, infusion therapies for autoimmune diseases, and arthritis injections that carry high out-of-pocket expenses. The pilot does not apply to every beneficiary nationwide. CMS designed the demonstration to randomly select geographic areas covering roughly 25% of beneficiaries who keep Original Medicare as their primary healthcare coverage [6].
Earlier federal estimates reported by STAT reporter John Wilkerson projected that combining GLOBE with the retail GUARD model—formally titled Guarding U.S. Medicare Against Rising Drug Costs—would cut spending by $27 billion over five years of operation. Federal officials originally envisioned mandatory participation across both Part B and Part D programs [3]. But CMS narrowed the immediate scope after signing voluntary pricing agreements with several pharmaceutical manufacturers. The agency will waive specific demonstration obligations for companies participating in those voluntary arrangements. Health officials say the model helps lower taxpayer costs while preserving patient care quality. Only qualifying patients within selected regions who receive covered therapies will see coinsurance reductions. The pilot tests international pricing formulas on a limited population [6].
PhRMA Challenges CMMI Statutory Authority
BIO is not fighting alone. On October 7, 2026, the Pharmaceutical Research and Manufacturers of America (PhRMA) filed suit in the U.S. District Court for the District of Columbia. The case, Pharmaceutical Research and Manufacturers of America v. Kennedy, names Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. and CMS Administrator Mehmet Oz as defendants [6].
PhRMA asked U.S. District Judge Royce C. Lamberth to strike down the rule under the Administrative Procedure Act. At the center of PhRMA’s complaint lies the Center for Medicare and Medicaid Innovation (CMMI), established under the Affordable Care Act in 2010. Congress created the innovation center under the health reform statute to test payment and service delivery models that reduce program expenditures while preserving patient care quality. PhRMA argues that CMMI exceeded that testing role by creating a mandatory drug-pricing system that Congress never authorized [6].
The trade group also raised constitutional questions regarding limits on delegating legislative power to executive agencies. PhRMA President and CEO Stephen J. Ubl said the industry “shares the administration’s goal of making medicines more affordable” but disputes CMS’ legal authority to impose the new system. Trade groups argue that tying reimbursement to foreign price caps will curb capital investment in high-risk biomedical research. The government disputes that conclusion. When announcing the final rule on September 30, CMS Administrator Mehmet Oz said Medicare patients and American taxpayers “have long paid substantially more for prescription drugs than people in comparable countries” [6].
Excluded Treatments and Savings Projections
To manage market exposure, CMS excluded several categories of medical treatments from the GLOBE pricing calculations. The final rule exempts therapies designated solely for rare diseases, plasma-derived products, and selected cell and gene therapies. In addition, biosimilars and their reference biological products drop out of the model once a biosimilar enters the commercial market [6].
By excluding these complex medical categories and exempting manufacturers with voluntary pricing agreements, CMS narrowed the demonstration to a small group of participating drugmakers. Because of these policy carve-outs, the government lowered its savings projection for the model to approximately $440 million in Medicare Part B spending over the demonstration period [6]. The revised total falls far below the first $27 billion estimate announced when health officials considered broader Part B and Part D mandates [3]. Executive agencies often adjust pilot models to test payment formulas without destabilizing therapy supplies. Broader debates over executive regulatory authority have also shaped congressional leadership debates on administrative technology policy. Disputes continue over the boundary between pilot testing and permanent policy [6].
Why Does Medicare Part B Face Lawsuits?
The central legal fight turns on how much authority Congress gave to federal agencies under healthcare legislation. In both the Washington and California complaints, industry lawyers rely heavily on the major questions doctrine [5]. Under this legal doctrine, executive agencies must show explicit congressional authorization when adopting policies of vast economic or political significance [6]. Because Medicare accounts for hundreds of billions in annual healthcare spending, trade groups argue that altering drug pricing mechanisms requires an express statute from lawmakers rather than agency rulemaking. If BIO proves that health officials lack explicit authority from lawmakers, a federal judge could invalidate the demonstration regardless of its projected impact on drug spending [5].
The confrontation echoes an earlier attempt during Donald Trump’s first presidential term. In December 2020, a federal court blocked an earlier most-favored-nation drug pricing rule because federal health officials bypassed required notice-and-comment procedures under the Administrative Procedure Act. This time, CMS followed standard notice-and-comment rulemaking before issuing its final September regulation [6].
As a result, the new lawsuits focus directly on substantive statutory authority instead of procedural notice shortcuts [6]. Over the next 90 days, legal analysts are monitoring two specific metrics: the assignment of the California judge and the government’s initial response. If the court questions the statutory authority of the Department of Health and Human Services (HHS), a preliminary injunction could halt the pilot before scheduled implementation begins. The outcome will dictate the scope of executive authority in pharmaceutical pricing [5].
Next Court Deadlines and Implementation Dates
Unless a federal court intervenes, the GLOBE model is scheduled to begin on January 1, 2027. That calendar gives manufacturers and participating healthcare providers three months to prepare before patient cost-sharing changes take effect. CMS announced that qualifying Medicare Part B beneficiaries in the selected regions could begin seeing lower coinsurance costs on April 1, 2027 [6].
Reductions will apply only to patients receiving specific covered therapies within the designated test areas. The agency plans to assess patient out-of-pocket savings during the five-year demonstration window. No federal judge has issued a ruling on either the PhRMA lawsuit in Washington or the BIO complaint in California [6]. Health officials at CMS did not comment on the litigation, but the Department of Health and Human Services is expected to defend its demonstration authority in court filings [1]. The upcoming rulings will determine whether Medicare can use international benchmark prices to calculate Medicare Part B drug rebates or whether drug pricing reforms must originate entirely within Congress. Federal courts will decide how far executive agencies can alter healthcare payments without legislative approval [6].
- ONLINE NEWS Wilkerson, J. (2026, November 7). BIO joins the legal fight against Medicare pilot that ties drug prices to peer countries. STAT. [Article Link]
- ONLINE NEWS Wilkerson, J. (2026, November 7). BIO joins the legal fight against Medicare pilot that ties drug prices to peer countries. STAT. [Article Link]
- ONLINE NEWS Wilkerson, J. (2026, February 24). Drugmakers lay out their legal arguments against Trump’s drug pricing experiments. STAT. [Article Link]
- ONLINE NEWS MedPath Trial. (2026, November 7). BIO Sues to Block Trump’s GLOBE Medicare Drug Pricing Model. MedPath Trial. [Article Link]
- ONLINE NEWS Möller, H. (2026, November 7). The BIO Lawsuit Against Medicare Pricing Is A Strategic Pivot In Industry Defense. Vesper. [Article Link]
- ONLINE NEWS Tjan, V. M. (2026, October 13). Drugmakers Sue to Block Trump Medicare Plan Tying Drug Costs to Lower Foreign Prices. Law Commentary. [Article Link]
APA 7: PerEXP Teamworks. (2026, November 8). BIO Sues to Block Trump Administration Medicare Part B Drug Model. PerEXP Teamworks. https://perexpteamworks.com/en/medicare-part-b-drug-pricing-lawsuit/
